News

Under the terms of the royalty purchase agreement, MacroGenics received a $70 million upfront payment for the sale of its royalty rights on global net sales of ZYNYZ. Following Sagard’s receipt of aggregate royalty payments totaling $140 million (or 2.0x), MacroGenics will resume collecting all future royalties on global net sales.

After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 million.

The Avance team is at Swiss HLG in Montreux, proudly representing Royalty Monetization. Excited for key insights on pharma deal-making and financing.

EMERYVILLE, Calif., U.S. and Lund, Sweden– May 27, 2025 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TA

Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before transaction costs.

Nuvation Bio to receive $150 million in royalty interest financing and $50 million in debt upon U.S. FDA approval of taletrectinib, with access to additional $50 million in debt at the Company’s option

We are excited to announce that our team will be attending the event and is interested in discussing RM opportunities.

In today's challenging fundraising environment for biotech and pharma companies innovative financing mechanisms are essential. Ligand Pharmaceuticals's recent $75 million royalty financing to further Castle Creek Biosciences Phase 3 clinical asset in DEB offers a compelling non-dilutive financing alternative. This deal creates a synthetic royalty on future revenue streams, unlocking value without diluting equity. Notably, the syndication of risk among multiple investors including XOMA Royalty, which is not commonly seen, further spreads risk and opens additional avenues for funding new therapies. Unlock the future of biotech financing—reach out to explore how royalty solutions can bridge your financing needs.

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into a royalty purchase agreement with Soleus Capital Credit Opportunities Fund I, L.P. (and any affiliated entity "Soleus"), an investment fund managed by Soleus Capital Management, L.P. ("Soleus Capital"), a US-based life sciences investment firm.

For Partnering & Investment at Hilton Zurich Airport Hotel.